miR-30c通过调节性结肠炎的目标基因VIP来影响性结肠炎的发生
Xiang Dong1,2, Yuling Zhan1,2, Minghui Yang2,3
1School of Life Science, Laboratory Animal Center, Bengbu Medical College, No. 2600 Donghai Road, Bengbu, 233030, China.
Scientific reports
|February 11, 2024
概括
缺少microRNA-30c会使小鼠的性结肠炎 (UC) 恶化,恶化疾病的严重程度和炎症. 这表明miR-30c通过调节血管活性肠 (VIP) 来保护大肠炎.
科学领域:
- 分子生物学分子生物学
- 免疫学 免疫学 免疫学
- 胃肠病学 胃肠病学
背景情况:
- 微RNA是表皮屏障功能和免疫反应的关键调节者.
- 微RNAs的失调与性结肠炎 (UC) 的病原发生有关.
- 在UC病变发生过程中,miR-30c的特定作用在很大程度上仍未被探索.
研究的目的:
- 调查miR-30c在性结肠炎 (UC) 病变发生过程中的作用.
- 通过使用硫酸盐 (DSS) 诱导的大肠炎模型,阐明UC中miR-30c的分子机制.
- 为了确定miR-30c对血管活性肠 (VIP) 基因表达的调节作用.
主要方法:
- 在野生型 (WT) 和miR-30c淘汰赛 (KO) 小鼠中使用了DSS诱导的结肠炎模型.
- 评估疾病活动指数,炎症因素和结肠组织病理学.
- 通过色酶记者测定,qRT-PCR,西部斑点和免疫组织化学验证了miR-30c对VIP表达的影响.
主要成果:
- miR-30c KO小鼠表现出明显更严重的DSS诱导性大肠炎表型.
- 这些包括较高的疾病活动指数,较大的体重减轻和结肠长度缩短.
- KO小鼠显示异常密码结构增加,粘液分泌减少,炎症因子概况改变.
结论:
- 缺少miR-30c似乎促进了DSS诱导的大肠炎的发展.
- miR-30c对VIP的目标调节作用可能是大肠炎发展的重要因素.
- miR-30c可以作为性结肠炎的潜在治疗标.
相关概念视频
Inflammatory Bowel Disease I: Ulcerative Colitis
185
Introduction
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
Inflammatory bowel disease, or IBD, encompasses a group of disorders characterized by chronic inflammation or ulceration of the gastrointestinal tract.
Risk Factors
The exact cause of IBD remains unclear, although it is believed to be due to a mix of genetic, environmental, microbial, and immune factors. Genetic factors are significant in determining susceptibility to IBD, with family history being a critical risk factor. Individuals with a first-degree relative who has IBD are at...
185
Drugs for Treatment of Ulcerative Colitis in IBD
141
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
141
MicroRNAs
3.0K
MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.0K
Inflammatory Bowel Disease V: Surgical Management
145
Surgical interventions for inflammatory bowel disease (IBD), which includes ulcerative colitis and Crohn's disease, are essential in managing symptoms and addressing complications. The selection of surgical procedures is contingent upon the specific conditions and complications that stem from these illnesses.
Here are some common surgical interventions for IBD:
Here are some common surgical interventions for IBD:
145
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
429
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
429


